New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes

Journal of Cardiovascular Pharmacology

Volumn 32, Issue SUPPL. 2, 1998, Pages

  Pahor, Marco ^a,d   Psaty, Bruce M ^b   Furberg, Curt D ^c  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute events; Amlodipine; Fosinopril; Hypertension; Nisoldipine; Type 2 diabetes

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; HYDROCHLOROTHIAZIDE; ISRADIPINE; NISOLDIPINE;

ANGINA PECTORIS; BLOOD PRESSURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MONITORING; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS;

EID: 0031722899     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800004-00004     Document Type: Conference Paper

References (24)

1. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996;276:1886-92.
2. Vitelli LL, Shahar E, Heiss G, et al. Glycosylated hemoglobin level and carotid intimal-medial thickening in nondiabetic individuals. The Atherosclerosis Risk in Communities Study. Diabetes Care 1997;20:1454-8.
3. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-45.
4. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
5. Schrier RW, Estacio RO, Jeffers B. Appropriate Blood Pressure Control in NIDDM (ABCD) Trial. Diabetologia 1996;39:1646-54.
6. Estacio RO, Jeffers BW, Hiatt WR, Biggi SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular events in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
7. Borhani NO, Mercuri M, Borhani PA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS): a randomized controlled trial. JAMA 1996;276:785-91.
8. Byington RP, Craven T, Furberg CD, Pahor M. Isradipine, raised glycosylated hemoglobin, and risk of cardiovascular events. Lancet 1997;350:1075-6.
9. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
10. Juhan Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-independent diabetes mellitus. Ann Med 1996;28:371-80.
11. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace PJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997;96:442-7.
12. Moriyama Y, Ogawa H, Oshima S, et al. Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction. Jpn Circ J 1997;61:308-14.
13. Oshima S, Ogawa H, Mizuno Y, et al. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 1997;134:961-6.
14. Galatius Jensen S, Wroblewski H, Emmeluth C, Bie P, Haunso S, Kastrup J. Plasma endothelin in congestive heart failure: effect of the ACE inhibitor, fosinopril. Cardiovasc Res 1996;32:1148-54.
15. Di Pasquale P, Valdes L, Albano V, et al. Early captopril treatment reduces plasma endothelin concentrations in the acute and subacute phases of myocardial infarction: a pilot study. J Cardiovasc Pharmacol 1997;29:202-8.
16. Mason RP. Probing membrane bilayer interactions of 1,4-dihydropyridine calcium channel blockers. Implications for aging and Alzheimer's disease. Ann NY Acad Sci 1994;747:125-39.
17. Mason RP, Moisey DM, Shajenko L. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol 1992;41:315-21.
18. Nehal M, Venugopal P, Baquer NZ. Changes in the lipid composition of red blood cells in hyperglycemic rats. Biochem Int 1990; 22:243-8.
19. Pahor M, Kritchevsky SB, Zuccalá G, Guralnik JM. Diabetes and risk of adverse events with calcium antagonists. Diabetes Care 1998;21:193-4.
20. Alderman MH, Madhavan S, Cohen H. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet 1998;351:216-7.
21. Heckbert SR, Psaty BM, Kaplan RC, et al. ACE inhibitors and MI risk in diabetics with hypertension [Abstract]. Circulation 1998; 97:826.
22. Pahor M, Furberg CD, Psaty BM. Treatment of hypertensive patients with diabetes. Lancet 1998;351:689-90.
23. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.
24. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996;9:342-60.